Regeneron Likely Facing New Gout Study Following Arcalyst “Complete Response” Letter
11:03 EDT 31 Jul 2012 | Elsevier Business Intelligence
FDA’s decision not to approve rilonacept for preventing gout flares was unsurprising, given its Arthritis Advisory Committee’s unanimous recommendation against the indication. Regeneron says FDA’s letter requests “additional clinical data,”..
Original Article: Regeneron Likely Facing New Gout Study Following Arcalyst “Complete Response” Letter
More From BioPortfolio on "Regeneron Likely Facing New Gout Study Following Arcalyst “Complete Response” Letter"
Biotech & Healthcare Channels
World News
Life Science Events
Corporate Database
Market Reports
Categories
Search BioPortfolio:
